Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Dynavax Technologies's share price for the quarter that ended in Dec. 2023 was $13.98. Dynavax Technologies's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 129.5 Mil. Therefore, Dynavax Technologies's market cap for the quarter that ended in Dec. 2023 was $1,810.8 Mil.
Dynavax Technologies's quarterly market cap
increased
from Jun. 2023 ($1,663.8 Mil) to Sep. 2023 ($1,908.2 Mil) but then
declined
from Sep. 2023 ($1,908.2 Mil) to Dec. 2023 ($1,810.8 Mil).
Dynavax Technologies's annual market cap
declined
from Dec. 2021 ($1,729.8 Mil) to Dec. 2022 ($1,357.7 Mil) but then
increased
from Dec. 2022 ($1,357.7 Mil) to Dec. 2023 ($1,810.8 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Dynavax Technologies's Enterprise Value for Today is $981.6 Mil.
Dynavax Technologies Market Cap Historical Data
The historical data trend for Dynavax Technologies's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Dynavax Technologies's Market Cap
For the Drug Manufacturers - Specialty & Generic subindustry, Dynavax Technologies's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dynavax Technologies's Market Cap Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dynavax Technologies's Market Cap distribution charts can be found below:
* The bar in red indicates where Dynavax Technologies's Market Cap falls into.
Dynavax Technologies Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Dynavax Technologies's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dynavax Technologies (NAS:DVAX) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Dynavax Technologies Market Cap Related Terms
Thank you for viewing the detailed overview of Dynavax Technologies's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Dynavax Technologies (Dynavax Technologies) Business Description
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DVAX has been successfully added to your 